Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia by Dale Horst, W et al.
Neuropsychiatric Disease and Treatment 2005:1(4) 349–355
© 2005 Dove Medical Press Limited. All rights reserved
349
ORIGINAL RESEARCH
Abstract: This study was designed to determine the feasibility and efficacy of long-term
nicotine replacement therapy (NRT) in helping persons with schizophrenia remain tobacco-
free. Fifty smokers with a diagnosis of schizophrenia or schizo-affective disorder and whose
symptoms had been stable for at least two months were enrolled in a program providing group
support and NRT (patches) in individually adjusted doses set to maintain baseline nicotine
intake. All participants attended weekly group support/motivation sessions. Smoking activity
was determined by measuring carbon monoxide levels in expired air. Participants who quit
tobacco use completely during the first three months were entered into a single-blind phase in
which they received either placebo or active nicotine patches for up to six additional months,
along with biweekly group sessions. Sixty days into the open-label phase, 66% of the subjects
had reduced their use of tobacco by at least 75%. After 90 days of open-label treatment, 18
subjects (36%) were tobacco-free and qualified to enter the six-month, single-blind phase,
eight on placebo and nine on active patches. A significantly greater proportion of those on
placebo (8 of 8) compared with those on active patches (3 of 9) relapsed prior to completion
of the 6-month period. This difference is statistically significant at the p = 0.009 level. The
results of this study indicate that long-term use of NRT is feasible and effective for sustained
tobacco-free success and may be an important strategy for reducing health risks due to tobacco
use in this special population.
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Introduction
The prevalence of tobacco use and nicotine addiction among persons with
schizophrenia in America is known to be substantially higher than among the general
population. Tobacco use rates of 70%–90% have been reported for persons with
schizophrenia, compared with approximately 23% in the overall United States
population (Hughes et al 1986; Goff 1992; Lohr and Flynn 1992; Ziedonis and George
1997; Lasser et al 2000; Araki 2002). Unfortunately, persons with schizophrenia are
subject to the same tobacco-related health risks as other tobacco users. As a result,
tobacco-related death rates among this population reflect its high prevalence of tobacco
use (Black 1998; Brown 2000; Ösby et al 2000).
Standard smoking cessation therapies are effective in helping smokers with
schizophrenia quit smoking. Motivational group sessions (Addington et al 1998),
NRT (Ziedonis and George 1997; George et al 2000), and bupropion (George et al
2002a) all appear to be useful in reducing smoking in this population. However,
when these therapies are completed, the relapse rates after six months are significant.
Addington et al (1998) reported that six months after the completion of seven
weekly group sessions, the “quit” rate had decreased approximately 70%. Following
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a three-month treatment with NRT, George et al (2000)
reported “quit” rates to decrease by 50%–70%. Similarly,
George et al (2002a) reported a 60% decrease in quit rates
six months following a nine-week treatment with bupropion.
Comparable relapse rates in the general population average
approximately 35% (Fiore et al 1994).
It has been suggested that nicotine may have a unique
role(s) in the brains of persons with schizophrenia (Dalack
et al 1998; Simosky et al 2002; Smith et al 2002;
McCloughen 2003; Vanable et al 2003; Newhouse 2004)
and that this may account for the high prevalence of nicotine
use by these persons. The accumulated evidence suggests
that successful tobacco cessation programs for persons with
schizophrenia may have to consider more than just the
addiction.
Hays et al (2001) have demonstrated that in a normal
population of smokers, extended treatment of the smoking
cessation drug bupropion is effective in relapse prevention
compared with placebo. The influence of extended
pharmacological treatment on relapse rate in a population
of smokers with schizophrenia has not been previously
studied. Therefore, we sought to determine the feasibility
and efficacy of extended NRT to help persons with
schizophrenia remain tobacco-free. Nicotine replacement
therapy (NRT) is known as an effective treatment for nicotine
addiction (Ziedonis and George 1997; George et al 2000)
in persons with schizophrenia. We report here the results of
a single-blind study in which continued NRT was compared
with placebo for six months after persons with schizophrenia
had successfully quit smoking through the use of NRT.
Methods
Fifty volunteers with a diagnosis of schizophrenia or schizo-
affective disorder were enrolled in the study. Subjects were
recruited through the collaborations with local mental health
support providers. Each subject gave written informed
consent. In addition to the above diagnoses, each subject
had to have stable psychiatric symptoms over the past two
months, use tobacco daily, be between 18 and 60 years of
age, and be able to participate in all of the study activities.
Subjects were not included who had cancer or clinically
significant cardiac, renal, gastrointestinal, pulmonary,
hepatic, endocrine, hematological, or neurological diseases.
Also not included were female subjects who were pregnant
or breastfeeding, or any subjects who were judged to be
unreliable.
Subjects provided medical and psychiatric histories and
a list of concomitant medications. Each subject was given a
standard 12-lead electrocardiogram, gave a blood sample
for a 24-item clinical chemistry panel, and gave a saliva
sample for cotinine determination. Levels of expired carbon
monoxide (CO), an indicator of recent smoking, were
determined with a Vitalograph-Breath Monitor (Catalog
Model #29700, Vitalograph Inc, Lenexa, Kansas, USA).
Subjects were administered a Clinical Global Evaluation
Scale to determine their relative levels of motivation,
cognitive functioning, and schizophrenia symptoms; and
they completed a modified Fagerström Test for Nicotine
Addiction (Heatherton et al 1991).
Following a review of the screening results by the study
staff and psychiatrist, subjects were assigned to groups of
no more than 10 individuals per group. The groups met with
a health educator weekly for one hour for 12 weeks. During
these 12 weeks, subjects were presented with a formal
curriculum designed for this population and based on the
“strengths model” (Rapp et al 1992). The “strengths model”
is designed to help the subjects become more aware of and
employ their strengths related to intelligence, competence,
motivation, and communication in accomplishing their goal
of quitting the use of tobacco. This model emphasizes their
successes rather than failures. The health educator was
experienced in working with subjects with schizophrenia
and was trained in providing tobacco cessation group
therapy. During regular office hours, the subjects were able
to contact the health educator by phone to ask questions or
to seek special assistance. Subjects were encouraged to set
a quit date within the first two weeks of their participation.
To minimize cravings and/or the emergence of symptoms
that may be reduced by nicotine, nicotine patch doses were
based on individual cotinine saliva levels. Saliva nicotine
and cotinine concentrations are highly correlated with those
in plasma (Rose 1993). Subjects were provided with
NicoDerm
® CQ
® patches at doses of 14, 21, or 42 mg/day
(Dale et al 1995). Subjects with cotinine levels less than
200 ng/mL were given 14 mg patches; those from 200 to
449 ng/mL received 21 mg patches; those from 450 to
900 ng/mL were given 42 mg (two 21 mg patches); and those
above 900 ng/mL received 63 mg (three 21 mg patches).
Patches were distributed to subjects at their quit date and
instructions were given to refrain from smoking while using
NRT. Subjects were encouraged to rotate the site of patch
applications. During the first and second months some
adjustments of nicotine doses were permitted to accom-
modate individual experiences with side effects or cravings.
No changes in nicotine dosage were permitted beyond that
time. At each weekly group session, subjects were monitoredNeuropsychiatric Disease and Treatment 2005:1(4) 351
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for expired carbon monoxide levels, smoking activity,
craving levels, and NRT tolerance. Subjects with CO levels
of 10 ppm or less were considered non-smokers.
A flow chart defining study phases is shown in Figure 1.
Subjects who did not set a “quit” date within two weeks,
who did not reduce their tobacco use by 75% after 60 days,
or who did not quit 100% after 90 days were discontinued
from the study. Those subjects who successfully quit tobacco
use after 90 days were randomly assigned (coin flip by
blinded third party) to receive either placebo patches
(SmithKline Beecham Consumer, Parsippany, NJ, USA) or
nicotine patches (Nicoderm® CQ®), with no change in dose
for six months. Subjects in this phase were blinded as to the
type of patches they received. Subjects attended group
sessions no less than every two weeks for informal
education/motivational discussions with the health educator.
During these sessions subjects were monitored for expired
CO levels, smoking activity, craving levels, and NRT
tolerance. Subjects with CO levels of less than 10 ppm were
considered non-smokers. Subjects with CO levels over
10 ppm for two consecutive weeks were considered relapsed
and discontinued from the study.
Differences in CO levels between baseline (screening
levels) and last observation carried forward were analyzed
by comparing means using paired t-tests (2-tailed).
For individuals who quit smoking, group differences in
outcome (relapse vs non-relapse) and single-blind treatment
type (active nicotine patch vs non-active placebo patch)
were analyzed by comparing proportions using Fisher’s
exact test (2-tailed). Group differences in outcome (relapse
vs non-relapse) and antipsychotic medication (on atypical
vs not on atypical antipsychotic) were analyzed by
comparing proportions using Fisher’s exact test (2-tailed).
In addition, a Kaplan-Meier Survival Analysis was
conducted to analyze the relationship of single-blind
treatment type and time to relapse. Significance was
calculated using log-ranks.
Relationships between smoking-associated variables
(pack-years, cotinine, and Fagerström rating) were assessed
using Kendall’s correlation coefficient for nonparametric
data and Pearson’s correlation coefficient for parametric
data. An alpha level of 0.05 was used to designate statistical
significance. All data in these analyses were tested for
normality. SPSS 11.0.1 for Windows
 was used for all
statistical analyses.
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50 subjects enrolled – Open-label phase
Weekly educational smoking cessation classes/ 
smoking activity assessments
Single-blind phase begins – subjects randomized to placebo or nicotine
Bi-weekly educational smoking cessation classes/smoking activity assessments
Figure 1 Study timeline.
a Smoking quit date due at 2 weeks – subjects discontinued if not set.
b Tobacco use to be reduced by 75% at 60 days – subjects discontinued if not successful.
c Tobacco use to be reduced by 100% at 90 days – subjects discontinued if not successful.
Table 1 Subject characteristics
Frequencies
Mean SD Range n = 50
Age 42.5 10.1 21–65
Sex 24 (48%) female
26 (52%) male
Pack years 39.9 28.4 1.3–112.0
Fagerstrom 7.4 1.5 4.0–10.0
Baseline cotinine
level 476.4 392.0 0.0
b–2094.0
Baseline carbon
monoxide level 29.9 21.3 1.0–110.0
Taking
antipsychotic?a 44 (100%) yes
Taking any
antidepressant?
a 32 (72.7%) yes
a Six cases missing who discontinued participation.
b One subject quit smoking shortly before study initiation.Neuropsychiatric Disease and Treatment 2005:1(4) 352
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Results
Characteristics of the study subjects are shown in Table 1.
The population was nearly equally divided between males
and females. All participants smoked cigarettes, the mean
pack-years was 40 and the mean Fagerström score was 7.4.
The antipsychotic medications and their chlorpromazine
equivalents taken by the subjects are listed in Table 2 along
with their study outcomes. No discernable pattern is evident.
Moreover, there was no significant effect of antipsychotic
type on smoking outcome. Thirty-two were taking
concomitant antidepressant medication primarily selective
serotonin reuptake inhibitors. Four subjects screened were
taking bupropion (150 mg/day); one did not return for
participation, two did not totally quit smoking and
consequently did not participate in the single-blind phase
of the study, and the fourth was included in the single-blind
nicotine patch group but relapsed after two months.
Six subjects were taking an antichloinergic
(5 benztropine, 1 trihexyphenidyl). Of these, two were
included in the single-blind phase. One subject on placebo
relapsed. The other on active patch remained tobacco-free
to the conclusion of the study. Of the 50 subjects enrolled:
10 failed to return for group sessions and did not receive
NRT; two withdrew from the study for personal reasons prior
Table 2 Frequencies of antipsychotic medications by study progress
Reduced
smoking by 75%,
Chlorpromazine equivalent: Single-blind but failed to Failed to reduce Discontinued
Total  Average mg/day (range) [SD] participants  reduce by 100% smoking by 75% participation
Risperidone 18 165.2 (50–400) [SD = 99.5] 4 (22.2%) [3]
a 9 (50.0%) 2 (11.1%) 3 (16.7%)
Olanzapine 11 266.7 (100–500) [SD = 134.7] 4 (36.4%) [2]a 5 (45.5%)  0 (0.0%) 2 (18.2%)
Clozapine 10 447.3 (60–1000) [SD = 398.7] 5 (50.0%) [3]
a 1 (10.0%)  0 (0.0%) 4 (40.0%)
Quetiapine fumarate 6 426.8 (267–667) [SD = 173.8] 1 (16.7%) [1]
a 3 (50.0%)  0 (0.0%) 2 (33.3%)
Ziprasidone 6 95.8 (17–133) [SD = 54.8] 2 (33.3%) [2]a 1 (16.7%)  0 (0.0%) 3 (50.0%)
Fluphenazine HCl 4 666.7 (500–1000) [SD = 288.7] 1 (25.0%) [0]
a 1 (25.0%)  0 (0.0%) 2 (50.0%)
Haloperidol 2 5000.0 (5000–5000) [SD = 0]  0 (0.0%) [0]
a 1 (50.0%)  0 (0.0%) 1 (50.0%)
Chlorpromazine HCl 2 300.0 (300–300) [SD = 0] 1 (50.0%) [1]a 1 (50.0%)  0 (0.0%)  0 (0.0%)
Trifluoperazine HCl 1 1000.0 (1000–1000) [SD = 0] 1 (100.0%) [1]
a  0 (0.0%)  0 (0.0%)  0 (0.0%)
Aripiprazole 1 300.0 (300–300) [SD = 0] 1 (100.0%) [0]
a  0 (0.0%)  0 (0.0%)  0 (0.0%)
None 3 – 2 (66.7%) [1]a 1 (33.3%)  0 (0.0%)  0 (0.0%)
a Indicates number relapsed.
Chlorpromazine equivalents adapted from Lehman and Steinwachs (1998); Woods (2003).
Table 3 Smoking characteristics of each study group
Baseline Final
Baseline carbon carbon
Fagerstrom Pack cotinine  monoxide  monoxide
rating years level level level
Discontinued participation (n = 12) Mean 8.0 30.2 548.5a 20.4 20.1
SD 1.2 27.4 447.3a 18.4 13.6
Failed to reduce smoking by 75% Mean 7.8 42.5 449.5 36.5 36.8
(n = 4) SD 1.5 35.2 177.0 17.6 16.1
Reduced smoking by 75%, but failed Mean 6.8 46.2 596.8 34.6 27.0
to reduce by 100% (n = 16) SD 1.4 33.9 515.4 26.0 15.1
Reduced smoking by 100%, Mean 7.7 37.9 274.8 30.3 20.2
but relapsed (n = 11) SD 1.5 16.9 146.9 15.1 7.6
Reduced smoking by 100% and Mean 7.3 44.0 420.3 30.9 1.6
maintained non-smoking state (n = 7) SD 1.8 30.2 230.9 24.4 2.4
Single-blind subjects receiving Mean 7.8 43.0 418.1 35.9 11.1
nicotine (n = 9) SD 1.2 25.2 201.2 23.3 14.3
Single-blind subjects receiving Mean 7.8 33.8 236.8 26.1 21.1
placebo (n = 8) SD 1.6 18.0 152.5 11.4 15.0
a One case missing.Neuropsychiatric Disease and Treatment 2005:1(4) 353
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to starting NRT; four failed to reduce their smoking rate by
75% within 60 days and were discontinued from the study;
16 failed to quit smoking completely by 90 days and were
discontinued from the study; and 18 quit smoking and
advanced to the single-blind extension (see Table 3 for the
characteristics of these groups). None of the subjects who
began NRT discontinued the study because of adverse
events, and none had any significant problem with skin rash
at the patch sites. Of the 42 subjects who used NRT, one
used 63 mg, 18 used 42 mg, 16 used 21 mg, and seven used
14 mg doses. Of those who participated in the single-blind
phase, four used 42 mg, nine used 21 mg, and three used
14 mg doses. Of the four subjects on 42 mg in single-blind,
two relapsed and two remained abstinent.
The results of the single-blind portion of the study are
shown in Figure 2 and Table 4. All eight of the subjects on
placebo patches relapsed within six months, while three of
nine subjects on nicotine patches relapsed. The difference
in smoking status between the placebo and active patch
groups was statistically significant at the p = 0.009 level
(Fisher 2-tailed test) and p ≤ 0.005 (log ranks). Figure 2
shows a substantial divergence in relapse between the two
treatment groups after two months of the single-blind phase.
The criterion for relapse was defined as two consecutive
measurements of CO above ten parts per million. Table 5
shows the number of months at which this criterion was
reached for each of the relapsed subjects and the number of
single episodes of CO measurements above 10 ppm prior to
reaching the relapse criterion. All of the relapsed subjects
showed evidence of intermittent smoking activity prior to
relapse while the smoke-free subjects consistently had CO
levels below 10 ppm.
Five subjects on their own volition attempted to reduce
or discontinue the use of patches during the initial phase of
the study. One subject remained tobacco-free throughout
the study without using patches. That individual was not
included in these analyses.
No significant correlation was observed between
baseline cotinine levels and Fagerström ratings or pack-
years. No significant differences were observed among the
groups shown in Table 2 with the exception of the final CO
levels that were significantly reduced in the individuals who
remained smoke-free throughout the single-blind phase of
the study.
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Figure 2 Comparison of time to relapse across treatment groups. The
differences seen in Figure 2 illustrate the effect of treatment type on time to
relapse. Subjects in the placebo group relapsed sooner than the nicotine group
with a 0.0% non-relapse at 6 months, and subjects in the nicotine group had
66.7% non-relapse at 6 months. This effect is statistically significant (log-
rank = 8.09, df = 1, p < 0.005).
Table 4 Relationship of nictotine or placebo patch and
smoking statusa
Relapsed Non-relapse Total
Nicotine patch observed 3 6 9
Placebo patch observed 8 0 8
Total 11 6 17
b
a Fisher’s exact (2-tailed) = 0.009.
b One individual who reduced smoking by 100% stopped using any patch, and
therefore is not included in either nicotine or placebo group.
Table 5 Total number of CO measures > 10 in single-blind
phase per subject
Month relapsed
 (of 6) #CO’s > 10
Placebo
2005 5 6
4011 3 3
5010 2 3
2011 4 2
5003 1 2
2012 2 2
3008 6 2
2001 3 2
Nicotine
3003 – 0
5006 – 0
5001 – 0
3005 – 0
4014 – 0
3002 – 0
5009 6 2
2009 2 2
3009 3 5
Abbreviations: CO, carbon monoxide.
Dashes denote participants who did not relapse.Neuropsychiatric Disease and Treatment 2005:1(4) 354
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Discussion
The results of this pilot study are encouraging.
Approximately two-thirds of the subjects reduced their
tobacco consumption by 75% within 60 days, and
approximately one-third quit completely within 90 days.
This compares favorably to quit rates previously reported
in subjects with schizophrenia using nicotine patches and
group therapies in open label protocols (Addington 1998;
George et al 2000). The significant difference in relapse
rates between placebo and active patch groups offer
particularly promising support for long-term NRT in persons
with schizophrenia who have quit using tobacco, although
the small sample size requires that our conclusions be
considered tentative. With a similarly designed study, Hays
et al (2001) have shown that long-term treatment with
bupropion after smoking cessation also reduces the rate of
relapse in a normal population.
Although this study was conducted in a single blind
fashion, the fact that the primary end point, CO levels in
expired air, is an objective measure along with the robust
response, suggest that the results are worthy of further
verification.
The contents of the education/support group sessions
were not formally evaluated; however, based on clinical
observations they did appear to play a role in the participants’
success by providing opportunities for mutual support and
encouragement, and providing focus seemed to contribute
to success. Nevertheless, the group sessions alone were not
adequate in preventing relapses.
The high prevalence of tobacco use among persons with
schizophrenia is widely discussed. Perhaps less appreciated
is the high level of addiction as evidenced by high
Fagerström nicotine dependence scores. The average
Fagerström score found in this study was 7.4. This compares
with scores of approximately 2.5–4.5 in nonschizophrenic
populations (Fagerström et al 1996; John et al 2003). Scores
reported in subjects with schizophrenia range from 5.6 to
9.04 (Addington 1997; George et al 2002b; Patkar et al 2002;
Avila et al 2003; Spring 2003). In two studies that compared
scores between subjects with and without schizophrenia,
those with schizophrenia had significantly higher
Fagerström scores (Avila et al 2003; Spring 2003). Another
study reported higher scores for smokers with schizophrenia
than those without, but the difference was not significant
(George et al 2002b). Overall, subjects with schizophrenia
appear to have higher than normal Fagerström nicotine
dependence scores. In spite of a high dependence level,
persons with schizophrenia do have a desire and motivation
to give up tobacco (Addington et al 1997), but may require
continued smoking cessation therapies to help them achieve
long-term success.
The results of this preliminary study suggest additional
investigations. First, confirmation of these results in a larger
number of subjects and for a longer duration would be useful
for determining the practical significance of these findings.
Second, information on the cost/benefit of long-term therapy
must be evaluated. Is the cost of the program justified by
improvements in the health of the individuals with a
concomitant reduction in healthcare costs and morbidity?
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